Abstract
Chordomas are relatively rare, slowly growing primary tumors of bone that arise from embryonic remnants of the notochord. These neoplasms typically occur in the axial skeleton mainly in the skull base (about 35%) and sacral region (about 50%) and have an overall peak distribution in patients aged 55-65 years. Chordomas are divided into conventional (the most common type), chondroid, and dedifferentiated types. Aggressive initial therapy, based on radical-maximal surgery followed by post-operative irradiation, improves overall outcome. Patients who relapse locally have a poor prognosis but both radiation and surgery can be used as salvage therapy. Radiation therapy alone may also be used in order to treat some patients with advanced, inoperable lesions or local recurrence. Proton beam irradiation has been reported as a very active form of irradiation for its peculiar physical properties. Chordomas are reported as tumors non sensitive to chemotherapy, even though anecdotal reports have been shown some sensitivity to molecularly targeted therapies.
Keywords: Chordoma, skull base, sacrum, radiotherapy, particle therapy
Current Drug Therapy
Title: Current Management of Chordoma
Volume: 5 Issue: 1
Author(s): Maurizio Amichetti and Dante Amelio
Affiliation:
Keywords: Chordoma, skull base, sacrum, radiotherapy, particle therapy
Abstract: Chordomas are relatively rare, slowly growing primary tumors of bone that arise from embryonic remnants of the notochord. These neoplasms typically occur in the axial skeleton mainly in the skull base (about 35%) and sacral region (about 50%) and have an overall peak distribution in patients aged 55-65 years. Chordomas are divided into conventional (the most common type), chondroid, and dedifferentiated types. Aggressive initial therapy, based on radical-maximal surgery followed by post-operative irradiation, improves overall outcome. Patients who relapse locally have a poor prognosis but both radiation and surgery can be used as salvage therapy. Radiation therapy alone may also be used in order to treat some patients with advanced, inoperable lesions or local recurrence. Proton beam irradiation has been reported as a very active form of irradiation for its peculiar physical properties. Chordomas are reported as tumors non sensitive to chemotherapy, even though anecdotal reports have been shown some sensitivity to molecularly targeted therapies.
Export Options
About this article
Cite this article as:
Amichetti Maurizio and Amelio Dante, Current Management of Chordoma, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010001
DOI https://dx.doi.org/10.2174/1574885511005010001 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stem Cells in Cartilage Repair: State of the Art and Methods to monitor Cell Growth, Differentiation and Cartilage Regeneration
Current Medicinal Chemistry The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Dose-Intensive Chemotherapy with Stem Cell Support as a Treatment Strategy for Bone and Soft-Tissue Sarcomas
Current Stem Cell Research & Therapy Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Inflammatory Signaling in Cartilage: MAPK and NF-κ B Pathways in Chondrocytes and the Use of Inhibitors for Research into Pathogenesis and Therapy of Osteoarthritis
Current Drug Targets Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma
Current Drug Targets Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Naturally Plant-Derived Compounds: Role in Bone Anabolism
Current Molecular Pharmacology Cartilage and Bone Extracellular Matrix
Current Pharmaceutical Design Molecular Links Between Diabetes and Osteoarthritis: The Role of Physical Activity
Current Diabetes Reviews Inorganic Phosphate as a Signaling Molecule: A Potential Strategy in Osteosarcoma Treatment
Current Pharmaceutical Design Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design MicroRNAs in the Intracellular Space, Regulation of Organelle Specific Pathways in Health and Disease
MicroRNA Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy